D. Heinzmann

发表

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.

Sung-Bae Kim, B. Melichar, C. Jackisch, 2012, The Lancet. Oncology.

Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion—With an application to the design of a clinical trial in acute myeloid leukemia

K. Rufibach, D. Heinzmann, A. Monnet, 2019, Pharmaceutical statistics.

Clinical Pharmacokinetics of Vemurafenib

J. Grippo, D. Heinzmann, Weijiang Zhang, 2017, Clinical Pharmacokinetics.

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial

J. Ahn, B. Melichar, X. Pivot, 2019, JAMA oncology.

A pragmatic adaptive enrichment design for selecting the right target population for cancer immunotherapies

M. Wolbers, D. Heinzmann, C. Berge, 2020, Pharmaceutical statistics.

Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (mBC) and CNS metastases (CNS mets).

Michael D. Taylor, D. Heinzmann, A. Shewade, 2018 .

HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.

Sung-Bae Kim, Shou‐Tung Chen, J. Ahn, 2016, European journal of cancer.

Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis

A. Schneeweiss, S. Swain, C. Jackisch, 2022, Cancers.

Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor setting

K. Rufibach, O. Humblet, Qixing Liang, 2022, Frontiers in pharmacology.

Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC).

J. Ahn, B. Melichar, X. Pivot, 2015 .

A cross-sectional study of biotechnology awareness and teaching in European high schools.

Y. Laizet, H. Vanderschuren, Klára Šimková, 2010, New biotechnology.

Evaluating parasite densities and estimation of parameters in transmission systems.

P. Torgerson, D. Heinzmann, 2008, Parasite.

An interactive map to assess the potential spread of Lymnaea truncatula and the free-living stages of Fasciola hepatica in Switzerland.

L. Hurni, U. Braun, P. Torgerson, 2008, Veterinary parasitology.

Development pathways for subcutaneous formulations of biologics versus biosimilar development

G. Bakalos, D. Heinzmann, A. Zharkov, 2019, Expert Review of Precision Medicine and Drug Development.

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

J. Baselga, M. Climent, W. Eiermann, 2014, The Lancet. Oncology.

A MECHANISTIC INDIVIDUAL-BASED TWO-HOST INTERACTION MODEL FOR THE TRANSMISSION OF A PARASITIC DISEASE

A. Barbour, P. Torgerson, D. Heinzmann, 2011 .

Time to extinction in a two-host interaction model for the macroparasite Echinococcus granulosus

D. Heinzmann, 2010 .

Case-control study to identify risk factors for bovine cysticercosis on farms in Switzerland

A. Mathis, P. Deplazes, H. Hertzberg, 2008, Parasitology.

Compound processes as models for clumped parasite data.

A. Barbour, P. Torgerson, D. Heinzmann, 2009, Mathematical biosciences.

SHOT NOISE PROCESSES FOR CLUMPED PARASITE INFECTIONS WITH TIME-DEPENDENT DECAY DYNAMICS

A. Barbour, P. Torgerson, D. Heinzmann, 2011 .

A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAFV600E mutation-positive metastatic melanoma

A. Joe, P. Munster, A. Daud, 2013, Cancer Chemotherapy and Pharmacology.

Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.

J. Jassem, V. Semiglazov, R. Bell, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation.

C. Jackisch, G. Minckwitz, J. Cortés, 2015, Future oncology.

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

M. Dowsett, R. Gelber, J. Baselga, 2013, The Lancet.

Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer

B. Lum, Chunze Li, D. Heinzmann, 2015, Cancer Chemotherapy and Pharmacology.

years versus 1 year of adjuvant trastuzumab for HER 2-positive breast cancer ( HERA ) : an open-label , randomised controlled trial

M. Dowsett, R. Gelber, J. Baselga, 2013 .

Weighted Approach for Estimating Effects in Principal Strata With Missing Data for a Categorical Post-Baseline Variable in Randomized Controlled Trials

Sabine Lauer, Shengchun Kong, Dominik Heinzmann, 2021, Statistics in Biopharmaceutical Research.

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy

A. Schneeweiss, R. Gelber, M. Buyse, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy

C. Harbron, S. Girish, V. Quarmby, 2022, Cancer reports.

Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males

M. Lehle, C. Wynne, B. Lum, 2013, Cancer Chemotherapy and Pharmacology.

Estimation of the transmission dynamics of Theileria equi and Babesia caballi in horses.

A. Barbour, P. Torgerson, S. Rüegg, 2008 .

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

A. Schneeweiss, R. Gelber, M. Buyse, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

On Identification of the Principal Stratum Effect in Patients Who Would Comply If Treated

K. Rufibach, M. Wolbers, B. Bornkamp, 2021, Statistics in Biopharmaceutical Research.

A filtered polynomial approach to density estimation

Dominik Heinzmann, D. Heinzmann, 2008, Comput. Stat..

An interactive map to assess the potential spread of Lymnaea truncatula and the free-living stages of Fasciola hepatica in Switzerland.

L. Hurni, U. Braun, P. Torgerson, 2008, Veterinary parasitology.

Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion—With an application to the design of a clinical trial in acute myeloid leukemia

K. Rufibach, D. Heinzmann, Annabelle Monnet, 2019, Pharmaceutical statistics.

J. Jassem, R. Bell, I. Láng, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).